Innate Pharma's Filing For Leukemia Drug Accepted In Europe
Zacks Investment Research | Jan 02, 2020 10:54PM ET
Innate Pharma S.A. (NASDAQ:IPHA) announced that the European Medicines Agency (EMA) has accepted its marketing authorization application (MAA) for its first-in-class medicine Lumoxiti. The company is seeking approval of Lumoxiti for the treatment of relapsed or refractory hairy cell leukemia (HCL) in adult patients who have received at least two prior systemic therapies including treatment with a purine nucleoside analog.
Rights to Lumoxiti were recently in-licensed by Innate from UK-based pharma giant AstraZeneca PLC (NYSE:AZN) . Upon submission of the MAA filing in Europe, Innate is entitled to pay a regulatory-based milestone fee of $15 million to AstraZeneca.
Lumoxiti is already marketed in the United States for the same indication in the given patient population. The drug was approved by the FDA in September 2018.
The regulatory filing in Europe was based on data from a pivotal phase III study of Lumoxiti. Data from the study showed that 36% of the patients treated with Lumoxiti achieved durable complete response defined as CR with a hematological remission maintained for minimum 180 days. The objective response rate (ORR) was 75% while 81% of patients with CR experienced eradication of minimal residual disease as reflected by MRD-negative status. Moreover, there was 61% probability that patients who achieved CR would maintain it even after five years
Shares of Innate rallied 13.5% following the EMA’s acceptance of the marketing application for Lumoxiti on Thursday.
If approved, Lumoxiti will become the first medicine to get the nod for relapsed/refractory HCL patients in Europe in more than 20 years. This can potentially change the standard of care for the given patient population.
We remind investors that shares of Innate started trading under the ticker symbol IPHA after the company completed its initial public offering in October 2019 on the Nasdaq stock exchange.
Per the company, AstraZeneca currently holds the biologics license application (BLA) for Lumoxiti in the United States and has been responsible for its commercialization. It was also responsible for filing the marketing application in Europe.
Zacks Rank & Stocks to Consider
Innate currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the biotech sector include NuCana PLC (NASDAQ:NCNA) and Agenus Inc. (NASDAQ:AGEN) , both sporting a Zacks Rank #1 (Strong Buy). You can see Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.